Core Insights - Natera, Inc. has launched EDEN, a large multi-center prospective study to evaluate its non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications [1] Group 1: Company Overview - Natera, Inc. is a global leader in cell-free DNA and precision medicine [1] Group 2: Industry Context - Preeclampsia affects approximately 5-8% of pregnancies and is a leading cause of maternal and neonatal morbidity [1]

2月5日，胡润研究院所发布的《2025胡润中国500强》榜单显示，500强企业的总价值增长21万亿元 （38%），达到77万亿元。平均价值增长415亿元，达到1530亿元。入围门槛提升至340亿元，较去年提 升75亿元，均创历史最高水平。 值得关注的是，科技产业持续担当增长引擎，半导体、生物医药、人工智能、新能源等硬科技赛道企业 数量与市值双升；科创板作为科技创新主阵地，多家企业强势入围；上海57家上榜企业，较2024年增加 7家，成为全国上榜企业数量增长最快的城市。 AI算力、半导体等赛道新面孔涌现 上述榜单数据显示，2025年中国非国有企业整体发展势头强劲，无论是上榜门槛、企业总价值，还是平 均价值，均实现大幅提升，民营经济的规模与质量同步升级。 从核心数据来看，《2025胡润中国500强》上榜门槛比上一年上升75亿元，达到340亿元。500强企业的 总价值增长21万亿元，达到77万亿元；平均价值增长415亿元，达到1530亿元。 胡润集团董事长兼首席调研官胡润表示，"过去一年，在新质生产力的驱动下，AI算力、消费电子、创 新药等领域表现亮眼，成为推动中国民营经济高质量发展的重要力量。近40%的今年上榜企 ...

1、Bob's Discount Furniture(BOBS) 美股IPO市场火热延续。 当地时间2026年2月5日，Bob's Discount Furniture、Eikon Therapeutics、Forgent Power Solutions、Hennessy Capital Investment VIII、Cantor Equity Partners VI同日在美股上市，共募资约25.34亿美元。 首日开盘，Bob's Discount Furniture每股报17美元，与发行价持平。开盘冲高后回落，至收盘每股报17.02美元，总市 值22.19亿美元。该公司在纽交所上市，股票代码BOBS。 该公司此次发行价为每股17美元，发行了1945万股，募集了3.31亿美元。根据招股书，Bob's Discount Furniture计划将 此次募集资金用于偿还债务。 Bob's Discount Furniture主要提供高性价比的家居产品，该公司通过低价优质产品+高效供应链+全渠道服务的组合， 在家居零售市场形成差异化优势。2025年前九个月营收17.19亿美元，净利润8070万美元。 2、Forge ...

Core Insights - The article discusses the role of the vagus nerve in tumor-brain communication and its implications for cancer immunity and progression [2][3][5]. Group 1: Tumor-Brain Communication - The study reveals a bidirectional communication between tumors and the brain mediated by the sensory-sympathetic axis, which plays a crucial role in inhibiting anti-cancer immunity and promoting cancer progression [3][6]. - Increased neural innervation of tumors is associated with poor cancer prognosis, highlighting the importance of understanding how the brain perceives and responds to tumors in peripheral organs [5][6]. Group 2: Mechanisms of Action - The research identifies a tumor-brain signaling axis that promotes tumor development by establishing an immunosuppressive tumor microenvironment [6]. - Vagal sensory neurons, which connect visceral organs to the brain, are shown to be involved in the signaling process, with specific neurons transmitting signals from lung tumors to brainstem nuclei, enhancing sympathetic output in the tumor microenvironment [6][7]. Group 3: Therapeutic Implications - Disruption of the sensory-sympathetic pathway through genetic, pharmacological, or chemogenetic methods can significantly inhibit lung tumor growth by enhancing anti-cancer immune responses [8][10]. - Targeting the tumor-brain communication pathway may provide new therapeutic strategies for visceral organ cancers [10].

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced Project Phase 2 peptide design activities with Neuland Laboratories Limited ("Neuland") under the parties' existing services agreement (please see news release dated January 8, 2026). Project Phase 2 of the collaboration focuses on the design and optimization of next-generation cell-penetrating peptides intend ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Q1 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrea Newkirk - SVP of Biotechnology Equity ResearchAndy Davis - SVP and Head of Global Cardiometabolic FranchiseChris Anzalone - President and CEODan Apel - CFOEdward Tenthoff - Managing DirectorJames Hamilton - Chief Medical Officer and Head of R&DJason Gerberry - Managing DirectorJoseph Thome - Managing DirectorMani Foroohar - Managing DirectorMike Ulz - Executive DirectorPatrick Trucchio - ...

Adaptive Biotechnologies (NasdaqGS:ADPT) Q4 2025 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsChad Robins - CEO and Co-FounderKarina Calzadilla - VP of Investor RelationsKyle Piskel - CFOSharon Benzeno - Chief Commercial Officer of Immune MedicineSusan Bobulsky - Chief Commercial Officer of MRDConference Call ParticipantsBill Bonello - AnalystDan Brennan - AnalystDavid Westenberg - AnalystMark Massaro - AnalystSebastian Sandler - AnalystSubbu Nambi - AnalystOperatorToday, and thank you fo ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Q1 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrea Newkirk - SVP of Biotechnology Equity ResearchAndy Davis - SVP and Head of Global Cardiometabolic FranchiseChris Anzalone - President and CEODan Apel - CFOEdward Tenthoff - Managing DirectorJames Hamilton - Chief Medical Officer and Head of R&DJason Gerberry - Managing DirectorJoseph Thome - Managing DirectorMani Foroohar - Managing DirectorMike Ulz - Executive DirectorPatrick Trucchio - ...

Financial Data and Key Metrics Changes - In Q4 2025, Illumina's revenue reached $1.16 billion, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on a constant currency basis [18][19] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [24] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [23] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [4][19] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with a notable 11% increase excluding China [19] - Sequencing instruments revenue was approximately flat year-over-year at $154 million, with strong placements of NovaSeq X [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting export restrictions [19] - Clinical market outside China grew 20%, driven by broader adoption of NGS-based testing [19] - Research and applied markets saw consumable sales remain roughly flat year-over-year, indicating ongoing uncertainty in the funding environment [20] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [9][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities to accelerate innovation [10][11] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in the second half of 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [15][27] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [15][29] - Management highlighted the importance of adapting to evolving market dynamics and customer needs, particularly in the context of multi-omics [14][78] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [5] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents, maintaining a strong balance sheet [25] - The company plans to change geographical reporting segments starting in Q1 2026 to better align with its commercial structure [31] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [33][36] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects continued momentum in clinical growth, with expectations for mid-teens growth, while acknowledging challenges in the research environment [40][42] Question: Instrumentation split between research and clinical - Over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [46][48] Question: Growth drivers in oncology and genetic applications - Oncology is expected to remain the main growth driver, with significant uptake in genetic profiling for various diseases [62][64] Question: BioInsight monetization strategy - Management outlined plans for monetizing BioInsight through specialized data and subscription-based models, indicating a multi-year opportunity [78][79]

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real ...